Tempus and New York City-based NYU Langone Health have formed a multi-year strategic collaboration to advance cancer research through molecular profiling and data-driven insights.
The partnership will support NYU Langone Health’s Center for Molecular Oncology at the Laura and Isaac Perlmutter Cancer Center, a pan-cancer initiative focused on understanding how disease biology evolves over time. Through the collaboration, researchers aim to enhance genomic diagnostics to improve patient outcomes, inform clinical practice and accelerate the development and validation of new diagnostic tools.
As part of the effort, the organizations are launching a prospective observational study. Patients enrolled in the study will undergo sequencing throughout their treatment journey to generate longitudinal molecular data, according to a Jan. 12 news release announcing the collaboration.
Beyond the initial study, the partnership includes plans for additional research focused on assay validation, biomarker discovery, biological modeling, real-world data analysis and the development of AI-powered predictive algorithms. This research is separate from Tempus’ existing role as a provider of next-generation sequencing testing services, the release said.
Leave a Reply